银屑病皮损组织中miRNA的差异表达分析及竹黄颗粒剂对其的干预作用
|
摘要
背景：
银屑病是临床最常见的慢性炎症性皮肤病之一,其发病为多因素参与、多基因改变及多阶段发展的病变过程,随着社会的发展与环境的改变,本病发病率逐年增高,因其发病原因不明,机制不清,治疗较为棘手,易于反复发生。银屑病发病机制的研究一直是皮肤科研究的重点,近年来,随着国内外学术界在小分子RNA领域研究的逐步深入,发现多种miRNA在皮肤生理病理等过程中发挥了极其重要的作用,部分特定的miRNA在某些皮肤病皮损组织中有异常表达,如皮肤肿瘤、银屑病、特应性皮炎等。同时从基因层面探讨银屑病的早期诊断、治疗及预防等课题已成为业界今后研究的主要方向之一。
目的：
运用基因芯片技术检测银屑病皮损miRNA表达谱,筛选其与正常人皮肤组织差异性表达的miRNA,并对差异miRNA进行靶基因预测及靶基因功能富集分析,构建银屑病差异表达miRNA与靶基因及基因功能调控网络,为银屑病基因层面机制研究提供依据,为银屑病早期诊治提供思路,为下一步开展miRNA靶基因功能及分子标志物研究提供线索。同时研究中药竹黄颗粒剂治疗银屑病患者前后皮损miRNA及血清细胞因子的表达差异,探索中医药治疗银屑病的作用机制,为中医药防治银屑病提供客观依据。
方法：
招募20名银屑病患者和15名健康志愿者,采集皮肤组织标本并用Trizo法提取RNA,运用Affymetrix miRNA2.0芯片检测正常人皮肤组织与银屑病患者典型皮损组织中miRNA表达谱,运用聚类分析软件(cluster3.0)分析差异表达的miRNA,采用实时荧光定量PCR方法验证部分差异miRNA。通过miRNA靶标基因数据库(miRGen3.0)预测靶基因,基于Gene Ontology数据库,对靶基因进行功能富集分析。20名银屑病志愿者进行2个月竹黄颗粒剂治疗后再次采集原发皮损样本,进行miRNA芯片检测,分析治疗前后miRNA表达差异及意义,同时采用酶联免疫吸附法(ELISA)检测治疗前后血清细胞因子并比较其差异性。
结果：
银屑病皮损组织中明显上调的miRNA有55个,明显下调的miRNA有12个,5个特异性miRNA (miR-31、miR-155、miR-192、miR-139-5p.miR-497)靶基因预测,得出AIRE、ADRA1D、AREG、IKBKE、POU6F1、BUB1B、 SMC3、SOCS1、DGKH、MAP3K12、OTC、REV3L、SLC26A6等33个关键基因。功能分析得出其调控了促分裂素原活化蛋白激酶信号通路(MAPK signaling pathway)、Wnt信号通路(Wnt signaling pathway)等30项主要的信号通路,主要通过调节炎症发生、细胞凋亡、血管内皮细胞增殖、新血管生成、体液免疫、蛋白激酶C(protein kinase C, PKC)、JNK信号转导与激活、有丝分裂细胞周期等,从而参与银屑病的发病。同时采用竹黄颗粒剂治疗2月后,总有效率为80%,PASI评分较治疗前有显著下降,显示对患者血清中IL-1、IL-2、IL-8、IL-10、IL-18、IFN-γ、TNF-α等细胞因子有明显下调作用,使之趋近于正常对照组。芯片结果显示对miR-192、miR-194、miR-3175、miR-18a、miR-629、miR-21、miR-25、miR-100、miR-199a-5p、miR-99a、miR-409-3p miR-125b、miR-99b等差异miRNA有显著双向调节作用。
结论：
1.miR-31等67个差异性miRNAs参与了银屑病的发病并扮演着重要角色；
2.差异性miRNA所调控的基因可能通过影响MAPKs等信号通路从而参与银屑病的发病,在细胞增殖、炎症形成、血管增生等方面构成影响；
3.miR-31等特异性miRNA有望成为银屑病早期诊断的潜在标记物和治疗靶点；
4.中药竹黄颗粒剂治疗银屑病疗效显著,对有些差异miRNA有双向调节作用,为中医药防治银屑病提供了客观依据；
5.研究结果为下一步开展银屑病相关miRNA靶基因功能及分子标志物研究提供了线索。
Background:
Psoriasis is one of the most common clinical chronic inflammation skin diseases. Many factors influence its incidence process, involving polygenetic change, complicated progress of pathological changes. With the development of the society and the environment changes, the rate of the disease increased year by year, due to its unclear etiology and mechanism, its treatment is difficult and easy to repeat. Therefore, research for psoriasis mechanism has caused the wild attention in the field of dermatology. In recent years, with the exploring to psoriasis progressing from domestic and foreign academic circles, it has been found that many minimal RNA (miRNA) play an important role in its pathogenesis and some of them were found abnormal expression in some skin lesions, such as skin cancer, psoriasis, atopic dermatitis. At the same time, from the perspectives of gene, studying on the psoriasis diagnosis, treatment, and prevention early has become one of the main research fields in the future all over the world.
Purpose:
Using gene chip technology testing psoriasis lesions miRNA expression patterns, the different miRNA expression from both abnormal and normal skin tissue are screened, and the differences in miRNA target genes prediction and target genes function enrichment are analysed, so as to construct a gene function regulation web for psoriasis differentially expressed miRNA and target genes and, providing the basis for the research of diagnosis and treatment of the psoriasis at the gene level, giving the clues for the next step in miRNA target genes function and molecular markers study. At the same time, the studies on influence of the traditional Chinese medicine ZhuHuang granules on the differences in psoriasis lesions and serum miRNA patients have been carried out before and after the treatment, so that the mechanism of Chinese medicine on the psoriasis treatment was explored, and more objective basis were provided for the Chinese medicine preventing and treating psoriasis
Methods:
20patients with psoriasis and15healthy volunteers were recruited, the skin and tissue samples from Trizo law to extract RNA were collected. Using Affymetrix miRNA2.0chip test the miRNA expression profile of normal skin organization and patients with psoriasis lesions in the typical organization. With clustering analysis software (cluster3.0) to analyze the differences of expression miRNA, and by use real time fluorescence quantitative polymerase chain reaction (PCR) to verify part miRNA differences. Through the miRNA target genes database (miRGen3.0) forecast target genes, Gene Ontology based on database of target genes function enrichment was analysed.20psoriasis volunteers lesions samples were collected again2months after the treatment of ZhuHuang granules for miRNA chip testing. Analyse the differences and significance on the miRNA expression before and after treatment. At the same time, using the method of ELISA to test differences on the serum cells factor before and after treatment.
Results:
There are55miRNAs obviously up-regulated in psoriasis lesions and12miRNAs of them obviously down-regulated. The result of target genes forecast for5specific miRNA (miR-31, miR-155, miR-192, miR-139-5p, miR-497) draw about33key genes,such as AIRE, ADRA1D, AREG, POU6F1, BUB1B IKBKE, SMC3, SOCS1, DGKH, MAP3K12, OTC, REV3L, SLC26A6etc. From the function analysis, its control the original mitogen activated protein kinase signal pathway (MAPK signaling pathway), Wnt signal pathway (Wnt signaling pathway)30other major signaling pathways, mainly by adjusting the inflammation occurs, the cell apoptosis, endothelial cell proliferation and angiogenesis, new humoral immune, protein kinase C (protein kinase C, PKC), JNK signal transduction and activation, mitotic cells cycle, so as to participate in the pathogenesis of psoriasis. At the same time the ZhuHuang granules miRNA expression of the intervention, and the results show the miR-192, miR-194, miR-3175, miR-18a, miR-629, miR-21, miR-25, miR-100, miR-199a-5p, miR-99a, miR-409-3p miR-125-b, miR-99-b miRNA have significant differences such as two-way of regulating functions.
Conclusion:
1.67differenct miRNAs such as miR-31involved in the incidence of psoriasis and played a very important role;
2. The regulation of genes miRNA differences may be affected by the MAPK signals of pathways that participate in the pathogenesis of psoriasis and prognosis, in cell proliferation, inflammation formation, the growth of blood vessels to constitute the influence, etc;
3. Five specific miRNAs such as miR-31is expected to become potential markers of psoriasis early diagnosis and therapeutic targets;
4. The effect of treating psoriasis with Chinese medicine Zhu-Huang granules is distinct. The granule have the two-way adjustment function to different miRNAs such as miR-192. The research provide the objective basis for treatment of psoriasis with traditional Chinese medicine;
5. The results provide clues for the next step for psoriasis miRNA target genes relating to function and molecular markers.
银屑病是临床最常见的慢性炎症性皮肤病之一,其发病为多因素参与、多基因改变及多阶段发展的病变过程,随着社会的发展与环境的改变,本病发病率逐年增高,因其发病原因不明,机制不清,治疗较为棘手,易于反复发生。银屑病发病机制的研究一直是皮肤科研究的重点,近年来,随着国内外学术界在小分子RNA领域研究的逐步深入,发现多种miRNA在皮肤生理病理等过程中发挥了极其重要的作用,部分特定的miRNA在某些皮肤病皮损组织中有异常表达,如皮肤肿瘤、银屑病、特应性皮炎等。同时从基因层面探讨银屑病的早期诊断、治疗及预防等课题已成为业界今后研究的主要方向之一。
目的：
运用基因芯片技术检测银屑病皮损miRNA表达谱,筛选其与正常人皮肤组织差异性表达的miRNA,并对差异miRNA进行靶基因预测及靶基因功能富集分析,构建银屑病差异表达miRNA与靶基因及基因功能调控网络,为银屑病基因层面机制研究提供依据,为银屑病早期诊治提供思路,为下一步开展miRNA靶基因功能及分子标志物研究提供线索。同时研究中药竹黄颗粒剂治疗银屑病患者前后皮损miRNA及血清细胞因子的表达差异,探索中医药治疗银屑病的作用机制,为中医药防治银屑病提供客观依据。
方法：
招募20名银屑病患者和15名健康志愿者,采集皮肤组织标本并用Trizo法提取RNA,运用Affymetrix miRNA2.0芯片检测正常人皮肤组织与银屑病患者典型皮损组织中miRNA表达谱,运用聚类分析软件(cluster3.0)分析差异表达的miRNA,采用实时荧光定量PCR方法验证部分差异miRNA。通过miRNA靶标基因数据库(miRGen3.0)预测靶基因,基于Gene Ontology数据库,对靶基因进行功能富集分析。20名银屑病志愿者进行2个月竹黄颗粒剂治疗后再次采集原发皮损样本,进行miRNA芯片检测,分析治疗前后miRNA表达差异及意义,同时采用酶联免疫吸附法(ELISA)检测治疗前后血清细胞因子并比较其差异性。
结果：
银屑病皮损组织中明显上调的miRNA有55个,明显下调的miRNA有12个,5个特异性miRNA (miR-31、miR-155、miR-192、miR-139-5p.miR-497)靶基因预测,得出AIRE、ADRA1D、AREG、IKBKE、POU6F1、BUB1B、 SMC3、SOCS1、DGKH、MAP3K12、OTC、REV3L、SLC26A6等33个关键基因。功能分析得出其调控了促分裂素原活化蛋白激酶信号通路(MAPK signaling pathway)、Wnt信号通路(Wnt signaling pathway)等30项主要的信号通路,主要通过调节炎症发生、细胞凋亡、血管内皮细胞增殖、新血管生成、体液免疫、蛋白激酶C(protein kinase C, PKC)、JNK信号转导与激活、有丝分裂细胞周期等,从而参与银屑病的发病。同时采用竹黄颗粒剂治疗2月后,总有效率为80%,PASI评分较治疗前有显著下降,显示对患者血清中IL-1、IL-2、IL-8、IL-10、IL-18、IFN-γ、TNF-α等细胞因子有明显下调作用,使之趋近于正常对照组。芯片结果显示对miR-192、miR-194、miR-3175、miR-18a、miR-629、miR-21、miR-25、miR-100、miR-199a-5p、miR-99a、miR-409-3p miR-125b、miR-99b等差异miRNA有显著双向调节作用。
结论：
1.miR-31等67个差异性miRNAs参与了银屑病的发病并扮演着重要角色；
2.差异性miRNA所调控的基因可能通过影响MAPKs等信号通路从而参与银屑病的发病,在细胞增殖、炎症形成、血管增生等方面构成影响；
3.miR-31等特异性miRNA有望成为银屑病早期诊断的潜在标记物和治疗靶点；
4.中药竹黄颗粒剂治疗银屑病疗效显著,对有些差异miRNA有双向调节作用,为中医药防治银屑病提供了客观依据；
5.研究结果为下一步开展银屑病相关miRNA靶基因功能及分子标志物研究提供了线索。
Background:
Psoriasis is one of the most common clinical chronic inflammation skin diseases. Many factors influence its incidence process, involving polygenetic change, complicated progress of pathological changes. With the development of the society and the environment changes, the rate of the disease increased year by year, due to its unclear etiology and mechanism, its treatment is difficult and easy to repeat. Therefore, research for psoriasis mechanism has caused the wild attention in the field of dermatology. In recent years, with the exploring to psoriasis progressing from domestic and foreign academic circles, it has been found that many minimal RNA (miRNA) play an important role in its pathogenesis and some of them were found abnormal expression in some skin lesions, such as skin cancer, psoriasis, atopic dermatitis. At the same time, from the perspectives of gene, studying on the psoriasis diagnosis, treatment, and prevention early has become one of the main research fields in the future all over the world.
Purpose:
Using gene chip technology testing psoriasis lesions miRNA expression patterns, the different miRNA expression from both abnormal and normal skin tissue are screened, and the differences in miRNA target genes prediction and target genes function enrichment are analysed, so as to construct a gene function regulation web for psoriasis differentially expressed miRNA and target genes and, providing the basis for the research of diagnosis and treatment of the psoriasis at the gene level, giving the clues for the next step in miRNA target genes function and molecular markers study. At the same time, the studies on influence of the traditional Chinese medicine ZhuHuang granules on the differences in psoriasis lesions and serum miRNA patients have been carried out before and after the treatment, so that the mechanism of Chinese medicine on the psoriasis treatment was explored, and more objective basis were provided for the Chinese medicine preventing and treating psoriasis
Methods:
20patients with psoriasis and15healthy volunteers were recruited, the skin and tissue samples from Trizo law to extract RNA were collected. Using Affymetrix miRNA2.0chip test the miRNA expression profile of normal skin organization and patients with psoriasis lesions in the typical organization. With clustering analysis software (cluster3.0) to analyze the differences of expression miRNA, and by use real time fluorescence quantitative polymerase chain reaction (PCR) to verify part miRNA differences. Through the miRNA target genes database (miRGen3.0) forecast target genes, Gene Ontology based on database of target genes function enrichment was analysed.20psoriasis volunteers lesions samples were collected again2months after the treatment of ZhuHuang granules for miRNA chip testing. Analyse the differences and significance on the miRNA expression before and after treatment. At the same time, using the method of ELISA to test differences on the serum cells factor before and after treatment.
Results:
There are55miRNAs obviously up-regulated in psoriasis lesions and12miRNAs of them obviously down-regulated. The result of target genes forecast for5specific miRNA (miR-31, miR-155, miR-192, miR-139-5p, miR-497) draw about33key genes,such as AIRE, ADRA1D, AREG, POU6F1, BUB1B IKBKE, SMC3, SOCS1, DGKH, MAP3K12, OTC, REV3L, SLC26A6etc. From the function analysis, its control the original mitogen activated protein kinase signal pathway (MAPK signaling pathway), Wnt signal pathway (Wnt signaling pathway)30other major signaling pathways, mainly by adjusting the inflammation occurs, the cell apoptosis, endothelial cell proliferation and angiogenesis, new humoral immune, protein kinase C (protein kinase C, PKC), JNK signal transduction and activation, mitotic cells cycle, so as to participate in the pathogenesis of psoriasis. At the same time the ZhuHuang granules miRNA expression of the intervention, and the results show the miR-192, miR-194, miR-3175, miR-18a, miR-629, miR-21, miR-25, miR-100, miR-199a-5p, miR-99a, miR-409-3p miR-125-b, miR-99-b miRNA have significant differences such as two-way of regulating functions.
Conclusion:
1.67differenct miRNAs such as miR-31involved in the incidence of psoriasis and played a very important role;
2. The regulation of genes miRNA differences may be affected by the MAPK signals of pathways that participate in the pathogenesis of psoriasis and prognosis, in cell proliferation, inflammation formation, the growth of blood vessels to constitute the influence, etc;
3. Five specific miRNAs such as miR-31is expected to become potential markers of psoriasis early diagnosis and therapeutic targets;
4. The effect of treating psoriasis with Chinese medicine Zhu-Huang granules is distinct. The granule have the two-way adjustment function to different miRNAs such as miR-192. The research provide the objective basis for treatment of psoriasis with traditional Chinese medicine;
5. The results provide clues for the next step for psoriasis miRNA target genes relating to function and molecular markers.
引文
[1]Griffiths-Jones S,Saini HK,van Dongen S,et al.miRBase:tools for microRNA genomics[J].Nucleic Acids Res,2008.36(8):154-158.
[2]TaganoV bigfield.KD,BoldinMP,BaltimoreD.MieroRNAs and immunity: tinyPlayersina Irnrnunity2007:26:133-137.
[3]Griffiths-Jones S,Saini HK,van Dongen S,et al.miRBase:tools for microRNA genomics[J]. Nucleic Acids Res,2008.36:154-158.
[4]SonkolyE,StahleM,PivaresiA.MicroRNAs:novel regulators in skin inflammation. Clin ExP Dermatol 2008;33:312-315.
[5]Hampton.MicroRNAs linked to pancreatic cancer[J]. JAMA.2007,297(9):937
[6]Zhang L,Coukos G. MicroRNAs:a new insight into cancer genome[J]. Cell Cycle,2006,5(19):2216-2219
[7]杨志波,唐雪勇.皮肤病相关MicroRNAs表达的研究进展[J].中国皮肤性病学杂志.2010，24(8)：760-762.
[81 Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis.Nature 2007;445:866-873
[91 Eniko Sonkoly,Tianling Weil,Peter C.J,et al.MicroRNAs:Novel Regulators Involved in the Pathogenesis of Psoriasis[J].PLoS ONE,2007,7(7):1-8.
[10]John R.Zibert,Marianne B.Loendorf,Thomas Litman,et al.MicroRNAs and potential target interactions in psoriasis[J]. Journal of Dermatological Science,2010,58(3):177-185.
[11]黄清平,张颖.寻常型银屑病的中医治疗概况[J].河北中医,2004，26(7)：547-549.
[12]杨志波,钱方,欧阳恒.竹黄颗粒剂Ⅱ号治疗银屑病100例临床观察[J].中医药导报，2005,11(1)：43-46.
[13]杨志波,刘炽,谭金华等.竹黄颗粒剂Ⅱ号对寻常型银屑病患者生活质量影响的研究[J].中国皮肤性病学杂志，2004，18(2)：93-94.
[14]杨志波.向亚萍，欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子a水平的比较[.J].中华皮肤科杂志,2000，33(6)：423.
[15]杨志波.欧阳恒,谭诚,等.竹黄颗粒剂对角质形成细胞增殖影响的实验研究[J].中国皮肤性病学杂志,2000,14(5)：309-311.
[16]杨志波.欧阳恒,许斌等.竹黄颗粒剂Ⅱ号对银屑病患者p内啡肽的影响[J].中国中西医结合皮肤性病学杂志2003.2(3)：166-167.
[17]杨志波,王-军文,向亚萍等.竹黄颗粒剂对培养人角质形成细胞增殖的影响[J].中国医师杂志,2001,3(3)：229-230.
[18]杨志波，陈晋广.胡伟才等.银屑病皮损基质金属蛋白酶2金属蛋白酶抑制因子2表达的研究[J].中华皮肤科杂志.2004.37(3)：168.
[19]杨志波,钱方，欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报.2004.10(12)：54-56.
[20]张志明，宋锐，彭华.等.用生物信息学挖掘玉米中的micro RNAs及其靶基因[J].作物学报，2010，36(8)：1324-1335.
[21]Michael Sand,Thilo Gambichler,Daniel Sand,et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science,2009,53:169-175.
[22]Dai Y,Huang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J].Lupus, 2007,16(12):939-46.
[23]Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases[J].BioDrugs,2007,21:97-104.
[24]Tai-You Ha.MicroRNAs in Human Diseases:From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases[J].Immune Network,2011,11(5):227-244.
[251 Shao-yao ying. miRNAs protocols[M].Humana Press Inc,2008,2(1):1-13.
[26]宋莉,王泽剑,等MicroRNAs的研究方法学及其与肿瘤发生发展关系的研究进展[J].中国肿瘤生物治疗杂志,2007.8，14(4)：397-400.
[271 Lu J,Getz G,Miska EA,et al.MicroRNA expression profiles classify human cancers[J].Nature.2005.435(4):834-838.
[281 Neely LA,Patel S,Garver J.elal.A single-molecule method for the quantitation of microRNA gene expression[J].Nat Methods,2006,3(3):41-46.
[291 Brown JR,Sanseau P.A computational view of miRNAs and their targets[J].Drug Discov.Tody,2005,10(1):595-601.
[301 Felicetti F, Errico MC, Bottero L,et al. The promyelocytic leukemia zinc finger-microRNA-22'/-222 pathway controls melanoma progression through multiple oncogenic mechanisms[J].Cancer Res.2008.68(7):2745-54.
[31]Schultz J, Lorenz P, Gross G,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth[J],Cell Res,2008,18(5):549-57.
[321 Worley LA, Long MD, Onken MD,et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling[J]. Melanoma Res,2008,18(1):184-90.
[33]汪阳.miR-199a调控黑色素瘤细胞转移相关基因的筛选[D].中南大学硕士论文,2011.
[341 Kunz M.Schultz J,Ibrahim S.Role of microRNA in melanoma progression[J]. Melanoma Res.2006,16(1):S53-S54.
[351 Hebert C,Norris K, Scheper MA,et al.High mobility group A2 is a target for miRNA-98 in head and neck squamous cell cacrinoma[J]. Mol Cancer.2007.20(6):5-15.
[361 Michael Sand,Thilo Gambichler.Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ [J] Journal of Dermatological Science,2009.53(9):169-175.
[371 Skalsky RL. Samols MA, Plaisance KB. Kaposi.s sarcoma-associated herpesvirus encodes an ortholog of miR-155[J].J Virol,2007,81(4):12836-45.
[381 Zavadil J.Narasimhan M.Blumenberg M.et al.Transforming growth factor-beta and microRNA:Mrna regulatory networks in epithelial plasticity[J].Cells Tissues Organs,2007.185(1-3):157-161.
[39]Dai YHuang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J]. Lupus, 2007,16(12):939-46.
[40]Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis [J].Arthritis Rheum,2010,62(6):1733-1743.
[41]张立民.系统性红斑狼疮MicroRNA表达谱和功能的初步研究[D].中国协和医科大学博士论文,2010：49.
[42]Divekar AA, Dubey S, Gangalum PR,et al.Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells:an apparent paradox in the setting of an inflammatory milieu. J Immunol,2011,186: 924-930.
[43]Bandres E,Cubedo E,Agirre X,et al.Identification by realtime PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J].Mol Cancer,2006,5(1):29-38.
[44]Valastyan S.Reinhardt F,Benaich N.etal.A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis [J].Cell,2009,137(6):1032-1046.
[45]王皓帆.miR-31是一种可抑制乳腺癌转移的多效性microRNA [J]中国病理生理杂志,2010，7：1260.
[46]Wang TS, Liu XB, Wong BY, et al. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue[J].Clin Cancer Res,2008,14(9):2588-2592.
[47]Kozaki K, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer[J]. Cancer Res,2008,68:2094-2105.
[48]Motoyama K,Inoue H.Takatsuno Y.etal.Over-and under-expressed microRNAs in human colorectal cancer[J].Int J Oncol,2009,34(4):1069-1075.
[49]Wang CJ,Zhou ZG,Wang L.etal.Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer[J].Dis Markers,2009,26(1):27-34.
[50]Xi Liu,Lorenzo F,Sempere,et al.MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors[J]. J Clin Invest,2010.120(4):1298-309.
[51]Valastyan S,Benaich N,Chang A,et al.Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis[J].Genes Dev,2009,15;23(22):2592-2597.
[52]Zhang Y,Guo J,Li D.et al.Down-regulation of miR-31 expression in gastric cancer tissues and its elinical significance[J]. Med Oncol.2009,14:685-689.
[53]Guo J,Miao Y,Xiao B,et al.Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues[J].J Gastroenterol Hepatol.2009.24(4):652-7.
[54]Creighton CJ,Fountain MD,Yu Z,et al.Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers[J].Cancer Res.2010,70(5):1906-1915.
[55]Schaefer A,Jung M,Mollenkopf HJ,etal.Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma[J].Int J Cancer,2010,126(5):1166-76.
[56]Hershkovitz Rokah O, Granot G, Ovcharenko A,etal.Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells. PLoS One.2012;7(4):1-12.
[57]王启鸣.miR-31促进食管鳞癌的侵袭转移[D].郑州大学博士论文,2011：13-14.
[58]Hezova R, Slaby O, Faltejskova Retal.MicroRNA-342,microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients.Cell Immunol 2010,260:70-74.
[59]范薇,唐元家,曲波,等.系统性红斑狼疮患者外周血细胞miR-31的表达[J].上海交通大学学报(医学版),2011,(1)：39-42.
[60]Mattie MD,Benz CC,Bowers J,etal.Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Mol Cancer,2006,5(5):24.
[61]赵东宇,王岩,罗迪.等.生物信息学中的MicroRNA预测研究[J].吉林大学学报(信息科学版),2008,26(3)：276-280.
[62]Zhang Y.miRU:an automated plant miRNA target prediction server.Nucleic Acids Res,2005,33:701-704.
[63]Yu XJ, Li CY, Dai HY, et al. Expression and localization of the activated mitogen-aeti-vated protein kinase in lesional psoriatic skin[J]. xp Mol Patho1, 2007 Dec,83(3):413-418.
[64]MeKenzie RC, Sabin E. Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratihecytes in psoriasis:a hypothesis[J]. Exp Dermatol, Aug 2003,12(4):337-345.
[65]FUnding AT, Johansen C, Kragballe K,et al. Mitogen-and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines[J]. J Invest Dermatol. Aug, 2006,126(8):1784-1791.
[66]Bhoumik A, Fichtman B, Derossi C.et al. Suppressor role of activating transcription factor 2(ATF2) in skin cancer[J]. Proc Natl Acad Sci U S A, 2008,105(5):1674-9.
[67]Wei G, Ku S, Ma GK,et al. HIPK2represses beta-eatenin-mediated-transcription, epidermal stem cell expansion, and skin tumorigenesis[J]. Proc Nail Acad sci U S A,2007,104(32):13040-5.
[68]庞勤,何黎MAPK信号传导通路与相关皮肤病[J].皮肤病与性病.2010,32(4)：15-17.
[69]马景德,齐秀芬MAPKs信号通路及其与疾病关联性的研究现状[J].临床军医杂志.2004,(2)：95-97.
[70]Johnson GL.Lapadat R.Mitogen-activated protein kinase pathways mediated by ERK, JNK. and p38 protein kinases[J]. Science,2002,298:1911-1912.
[71]Cunningham D. Humblet Y. Siena S, et al.Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med,2004,351:337-345.
[72]高泽俊，袁小青,沈捷,MAPK通路在Leptin促人乳腺癌细胞系增殖中的机制研究[J].南京医科大学学报(自然科学版),2008.28(11)：1410-1414.
[73]梁荔,盛红光,刘雯MAPK信号转导通路在DHA诱导胃癌细胞凋亡中的作用[J].中国现代普通外科进展,2009.12(12)：26-29.
[74]刘雯,马金龙,林万润MAPK信号转导蛋白在高温致神经管畸形中的表达[J].中国病理生理杂志,2010,26(3)：472-476.
[75]Msantos SDM, Verveer PJ, Bastiaens PIH. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate[J].Nat Cell Biol,2007,9(3):324-330.
[76]赵海生,顾军MAPK信号转导通路与银屑病[J].中国皮肤性病学杂志,2007,21(3)：184-186.
[77]C.Johansen.k,Kragball,Brinster,R.L,et al.The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin cutaneous[J],Biology,2005.10(11):1365-1369.
[78]Longo K A, W right W S, Kang S, et al. W ntlOb in hibits development of white and brown adipose tissues[J]. J Biol Chem,2004, 279(34):35503-35509.
[79]Ross S E, Hemati N, Longo KA, gt al. MacDougald, Inhibi-tion of adipogenesis by Wnt signaling[J]. Science.2000.289:950-953.
[80]XingY, Clements W K, Kimelman D, et al. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. Genes Dev,2003,17:2753-2764.
[81]Reischl J, Sehwenke S, Beckman JM, et al. Increased expression of wnt5a in psoriatic plaques [J]. J Invest Dermatol,2007,127(1):163-9.
[82]Saldanha G, Ghura V, PoRer L, et al. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation[J]. Br J Dermato 1, 2004,151(1):157-64.
[83]Taki M, KamataN, Ygkoyama K, et al. Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells[J]. Cancer Sci,2003,94(7):593-7.
[841 Seto ES, Bellen HJ. The ins and outs of Wingless signaling[J]. Trends Cell Biol.2004.14(1):45-53.
[85][13]Eunkyung C, Paul WC, Parkos CA, et al. Amphiregulin causesfunc-tional dowmcgnlation ofadberensjunctions in psoriasis[J]. Invest Dermatol 2005,124(6):1134-4o.
[86]刘国刚，熊霞,Wnt/β-catenin信号通路与银屑病相关性研究进展[J].西南军医,2012,(1)：109-110.
[87]范瑞强，邓丙戌,杨志波.中医皮肤性病学[M].北京：中国中医药出版社出版，2009,566.
[88]陈洪铎.临床诊疗指南-皮肤病与性病分册[M].北京：人民卫生出版社.2006.109-113.
[891 Kerkhof PC. The psoriasis area severity index and altemafive approaches for the assessment of severity:persisting areas of confusion[J].Br J Dermato,1997, 137(4):661-662.
[90]杨水祥miRNA药物治疗前景[C].第六届钱江国际心血管病会议暨2012浙江省心血管病年会.钱江：2012.
[91]李育敏,费嘉,MicroRNA与血液系统肿瘤发生、诊断和治疗[J].中国病理生理杂志,2009,(11)：2225-2229.
[92]Ambros V.The functions of animal microRNAs[J]. Nature,2004,431:350-355.
[93]microRNA在人类癌症治疗中的应用前景[J].分子诊断与治疗杂志,2010,(6).413-416.
[94]王娟,李建民.免疫治疗银屑病对细胞因子影响的研究进展[J].广西医学,2009,(9)：1357-1359.
[95]雷漾,郑和义.T淋巴细胞及细胞因子与银屑病的发病关系[J].国际皮肤性病学杂志,2007,(6)：346-348.
[96]茹雪莹,徐丽敏,吴泰相.白介素-2与银屑病相关性的Meta分析[J].中国中西医结合皮肤性病学杂志,2009,(1)：51-55.
[97]王支琼,李家文.银屑病患者白介素-18及其受体的辅助性非结合链和白介素-18结合蛋白mRNA的表达[J].中华皮肤科杂志,2003,(7)：403.
[981 Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis[J]. Arch Dermatol Res.2001,293:334-342
[99]王学军,陶以成,胡二为.丹槐银屑浓缩丸对豚鼠银屑病模型血清INF-γ、IL-6的影响[J].中国中医药科技,2010,(4)：286.
[100]甄莉,吴媛.黄芪注射液对银屑病外周血淋巴细胞白介素-2及其受体的影响[J].中国中西医结合皮肤性病学杂志,2006,(2)：63-65.
[101]林燕,孙虹,刘艳萍,等.消银合剂治疗血热证银屑病疗效及血清干扰素-γ、白介素-10检测[J].中国中西医结合皮肤性病学杂志,2008,(2)：76-79.
[102]朱黎明,李英,孙兆圣,等.消银脐贴治疗寻常型银屑病24例临床研究[J].江苏中医药,2011,(5)：40-41.
[103]王丽华,张蕾,刘欣,等.养血解毒汤对血燥型银屑病患者血清免疫细胞因子的调节[J].辽宁中医药大学学报,2010,(11)：69-71.
[104]吴胜利,许能,陈建明,等.解毒化疲汤治疗银屑病的临床和实验研究[J].中华皮肤科杂志,2004,37(3)：133-34.
[105]宋茹,袁继民,王媛媛.复方苦参注射液治疗银屑病的实验研究[J].中国现代应用药学杂志,2002,19(3)：177-178.
[106]景海霞,盛晚香,段德鉴.当归多糖对豚鼠银屑病样皮损中PCNA表达的影响.中国皮肤性病学杂志,2008,22(1)：11-13.
[107]杨志波,向亚萍,欧阳恒银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子αα水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[1]Ambros V.The functions of animal microRNAs[J]. Nature,2004,431:350-355.
[2]Griffiths-Jones S,Saini HK,van Dongen S,et al.miRBase:tools for microRNA genomics[J].Nucleic Acids Res,2008.36:154-158.
[3]Shao-yao ying. miRNA protocols[M].Humana Press Inc,2008,2:1-13.
[4]Eniko Sonkoly.Tianling Weil,Peter C.J,et al.MicroRNAs:Novel Regulators Involved in the Pathogenesis of Psoriasis[J].PLoS ONE,2007,7(7):1-8.
[5]E.Sonkoly.M.Stahle.A.Pivarcsi.MicroRNAs:novel regulators in skin inflammation[J]. Clinical and Experimental Dermatology,2008,33:312-315.
[6]Eniko Sonkoly,Mona Stahle,Andor Pivarcsi. MicroRNAs and immunity:Novel players in the regulation of normal immune function and inflammation[J].Seminars in Cancer Biology,2008,18:131-140.
[7]Lee,R.C,Feinbanum,R.L,Ambros,V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity ti lin-14[J].Cell,1993,75:843-854.
[8]Lau,N.C,Lim.L.P,Weinstein.E.G, Bartel,D.P.An abundant class of tiny RNAs with probable regulatory roles in Caenorhabiditis elegans.Science[J].2001,294:858-862.
[9]Lagos-Quintana.M.Rauhut.R.Meyer et al.New miRNA from mouse and human[J].RNA.2003,9:175-179. Calin GA,Sevignani C.Dumitru CD,et al.Hunman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J].Proc Natl Acad Sci USA,2004,101:2999-3004.
[11]薛京伦,等.表观遗产学—原理、技术与实践[M].第一版,上海：上海科技出版社.2006.12：131-146.
[12]Khvorova.A,Reynolds.A.Jayasena.S.D.Functional siRNAs and miRNA exhibit strand bias[J].Cell,2003.115:209-216.
[13]Soken T.Yasushi O,Gozoh T.MicroRNA:biogenetic and functional mechanisms and involvementsin cell differentiation and cancer[J].J Pharmacol Sci,2006,101:267-270.
[14]Lu J,Getz G,Miska EA.et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435:834-838.
[15]Neely LA,Patel S.Garver J,elal.A single-molecule method for the quantitation of microRNA gene expression[J].Nat Methods,2006,3:41-46.
[16]Mattie MD,Benz CC,Bowers J,etal.Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Mol Cancer.2006,5:24.
[17]Brown JR,Sanseau P.A computational view of miRNA and their targets[J].Drug Discov.Tody,2005,10:595-601.
[18]Landthaler M.Yalcin A,Tuschl T.The human DiGeorge syndrome critical region gene 8 and Tts D.melanogaster homolog are required for miRNA biogenesis[J].Curr boil,2004.14:2162-2167.
[19]宋莉,王泽剑,等.MicroRNAs的研究方法学及其与肿瘤发生发展关系的研究进展[J].中国肿瘤生物治疗杂志,2007.8,14(4)：397-400.
[20]Michael Sand,Thilo Gambichler, Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science.2009.53:169-175.
[21]Zhang L,Huang J,Yang N.et al.microRNAs exhibit high frequency genomic alterations in human cancer[J].Proc Natl Acad Sci USA.2006.103:9136-41.
[22]Feramisco JD, Casey R. Tsao H. Recent updates on genetics:teaching old dogmas new tricks[J].Pediatr dermatol,2008.25(1):99-108.
[23]Gaur A.Jewell DA. Liang Y,et al. Characterizationof and their biological correlates in human cancer cell lines[J].Cancer Res.2007,67:2456-68.
[24]Bemis LT. Chen R, Amato CM.et al.Robinson WA:MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines[J]. Cancer Res,2008,68:1362-8.
[25]Felicetti F, Errico MC, Bottero L,et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms[J].Cancer Res,2008,68:2745-54.
[26]Schultz J, Lorenz P, Gross G,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth[J],Cell Res,2008,18:549-57.
[27]Worley LA, Long MD, Onken MD,et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling[J].Melanoma Res,2008,18:184-90.
[28]Kunz M,Schultz J,Jbrahim S.Role of microRNA in melanoma progression[J].Melanoma Res,2006,16(suppl):S53-S54.
[29]Hebert C,Norris K, Scheper MA.et al.High mobility group A2 is a target for miRNA-98 in head and neck squamous cell cacrinoma[J]. Mol Cancer.2007,20 (6):5-15.
[30]Michael Sand.Thilo Gambichler.Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science, 2009,53:169-175.
[31]Skalsky RL, Samols MA, Plaisance KB. Kaposis sarcoma-associated herpesvirus encodes an ortholog of miR-155[J].J Virol,2007.81:12836-45.
[32]Zavadil J.Narasimhan M.Blumenberg M.et al.Transforming growth factor-beta and microRNA:Mrna regulatory networks in epithelial plasticity[J].Cells Tissues Organs,2007,185(1-3):157-161. ] Dai Y,Huang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J].Lupus. 2007,16(12):939-46.
[34]Lebwohl M.Psoriasis[M]. The Lancet.2003.361:1197-1204.
[35]Vickery BP.Skin barrier function in atopic dermatitis[J].Curr Opin Pediatr, 2007.19:89-93.
[1]Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis.Nature 2007;445:866-873
[2]刘旭,刁骋.银屑病发病机制的研究进展[J].沈阳医学院学报,2007.12,9(4)：248-250.
[3]张学军.全基因组关联分析对银屑病遗传学研究的启示[J].浙江大学学报(医学版)2009,38(4)：334-336.
[4]Gallinaro H.A 4.2 kb upstream region of the human comeodesmosin gene directs site-specific expression in hair follicles and hyperkeratotic epidermis of transgenie mice[J].J Invest Derm atol,2004.122:730-738.
[5]Foerster J,Nohe I,Schweiger S,et al. Evaluation of the IRF-2 gene as a candidate for PSORS3[J].J Invest Dermatol.2004,122(1):61-64.
[6]Hufmeier U,Lascorz J,Traupe H,et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confinns a role in susceptibility to psoriasis vulgaris[J]. J Invest Dermatol,2005.125 (5):906-912.
[7]Rainer Z,Robert,E,Lukas K,et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Junproteins[J]. Nature.2005,437: 369-375.
[8]ZHANG X J, HUANG W, YANG S, et al.,Psoriasis genome-wide association study identifies susceptibility variants with in LCE gene cluster at 1q21 [J]. Nat Genet,2009,41 (2):205-210.
[9]徐娟,贾随旺,钟绮丽,等.银屑病皮损细胞凋亡的研究[J].岭南皮肤性病科杂志,2004,11(2)：91-93
[10]陈静,鲁建云,廖朝晖,等.角质形成细胞凋亡与银屑病病情的关系[J].中南大学学报(医学版),2006,31(6)：936-939
[11]Oieda R,Sanchez Regana M,Massana J,et al. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study [J]. J Dermatolog Treat,2005,16(4):238-241.
[12]Banno T,Gazel A,Blumenberg M. Efects of tumor necrosis factor-a(TNF-a) in epidermal keratinocytes revealed using global transcriptional profiling[J]. J Biol Chem,2004,279:32633-32642.
[13]Sabat R,Wallace E,Endesfelder S.et al. IL-19 and IL-20:two novel cytokines with importance in inflammatory diseases[J]. Expert Opin TherTargets,2007,11(5):601-612.
[14]Gamze P,Regien MR,Jan DB. In vitro and in situ expression of IL-23 buy keratinocytes in healthy skin and psoriasis lesions:enhanced expression in psoriatic skin[J]. J Immunol,2006.176 (3):1908-1915.
[15]路又璐.17味中药对培养的表皮细胞增殖的影响[J].临床皮肤科杂志,1996,25(4)：202.
[16]刘晓明,孙秀坤,齐欣等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素-1的影响[J].中华皮肤科杂志,2001,34(4)：282-283.
[17]吴胜利,许能,陈建明,等.解毒化疲汤治疗银屑病的临床和实验研究[J].中华皮肤科杂志,2004,37(3)：133-34
[18]宋茹,袁继民,王媛媛.复方苦参注射液治疗银屑病的实验研究[J].中国现代应用药学杂志,2002,19(3)：177-178
[19]景海霞,盛晚香,段德鉴.当归多糖对豚鼠银屑病样皮损中PCNA表达的影响.中国皮肤性病学杂志,2008,22(1)：11-13
[20]杨志波,向亚萍,欧阳恒银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子α水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[21]王万春,熊佳玫,马文军,等.中药清银解毒汤治疗寻常型银屑病及血清TNF-α、IL-8水平检测[J].辽宁中医杂志,2009,36(2)：242-243
[22]于延,刘晓明,侯素春.凉血活血汤治疗寻常型银屑病临床观察及其对血IL-8的影响[J].中国麻风皮肤病杂志,2005,21(9)：712-714
[23]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771
[24]陈红,王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J].中药材,2004,27(11)：885-886
[25]马学伟,陈国荣,朱风梅,等克银Ⅰ号胶囊治疗进行期寻常型银屑病40例临 床观察[J].中国中医药科技,2000,7(6)：396
[26]王乖娟,刘卫兵,荆鲁华,等.银屑宁胶囊对心得安致豚鼠银屑病样皮损N0和MDA水平的影响[J].中国中西医结合皮肤性病学杂志,2005,4(3)：166.
[27]刘群英,钟以泽,陈德华,等.白疙软膏治疗银屑病的实验研究[J].广西医科大学学报,2006,23(3)：421-422.
[28]王禾,王萍,孙丽蕴,等.凉血活血胶囊治疗银屑病血热证的临床观察及外周血淋巴细胞亚群检测[J].中国皮肤性病学杂志,2004,18(3)：176-177
[29]王丽江,张地君,粟小文.寻常型银屑病患者丹参治疗前后甲皱微循环变化比较析[J].皮肤病与性病,2001,23(4)：3
[30]娄卫海,张志礼,邓丙戌,等.凉血活血汤治疗进行期银屑病的临床及实验研究[J].华皮肤科杂志,1999,32(2)：80-81.
[31]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿留坏死因子和介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771.
[2]TaganoV bigfield.KD,BoldinMP,BaltimoreD.MieroRNAs and immunity: tinyPlayersina Irnrnunity2007:26:133-137.
[3]Griffiths-Jones S,Saini HK,van Dongen S,et al.miRBase:tools for microRNA genomics[J]. Nucleic Acids Res,2008.36:154-158.
[4]SonkolyE,StahleM,PivaresiA.MicroRNAs:novel regulators in skin inflammation. Clin ExP Dermatol 2008;33:312-315.
[5]Hampton.MicroRNAs linked to pancreatic cancer[J]. JAMA.2007,297(9):937
[6]Zhang L,Coukos G. MicroRNAs:a new insight into cancer genome[J]. Cell Cycle,2006,5(19):2216-2219
[7]杨志波,唐雪勇.皮肤病相关MicroRNAs表达的研究进展[J].中国皮肤性病学杂志.2010，24(8)：760-762.
[81 Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis.Nature 2007;445:866-873
[91 Eniko Sonkoly,Tianling Weil,Peter C.J,et al.MicroRNAs:Novel Regulators Involved in the Pathogenesis of Psoriasis[J].PLoS ONE,2007,7(7):1-8.
[10]John R.Zibert,Marianne B.Loendorf,Thomas Litman,et al.MicroRNAs and potential target interactions in psoriasis[J]. Journal of Dermatological Science,2010,58(3):177-185.
[11]黄清平,张颖.寻常型银屑病的中医治疗概况[J].河北中医,2004，26(7)：547-549.
[12]杨志波,钱方,欧阳恒.竹黄颗粒剂Ⅱ号治疗银屑病100例临床观察[J].中医药导报，2005,11(1)：43-46.
[13]杨志波,刘炽,谭金华等.竹黄颗粒剂Ⅱ号对寻常型银屑病患者生活质量影响的研究[J].中国皮肤性病学杂志，2004，18(2)：93-94.
[14]杨志波.向亚萍，欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子a水平的比较[.J].中华皮肤科杂志,2000，33(6)：423.
[15]杨志波.欧阳恒,谭诚,等.竹黄颗粒剂对角质形成细胞增殖影响的实验研究[J].中国皮肤性病学杂志,2000,14(5)：309-311.
[16]杨志波.欧阳恒,许斌等.竹黄颗粒剂Ⅱ号对银屑病患者p内啡肽的影响[J].中国中西医结合皮肤性病学杂志2003.2(3)：166-167.
[17]杨志波,王-军文,向亚萍等.竹黄颗粒剂对培养人角质形成细胞增殖的影响[J].中国医师杂志,2001,3(3)：229-230.
[18]杨志波，陈晋广.胡伟才等.银屑病皮损基质金属蛋白酶2金属蛋白酶抑制因子2表达的研究[J].中华皮肤科杂志.2004.37(3)：168.
[19]杨志波,钱方，欧阳恒.竹黄颗粒剂Ⅱ号对降钙素基因相关肽的影响[J].湖南中医药导报.2004.10(12)：54-56.
[20]张志明，宋锐，彭华.等.用生物信息学挖掘玉米中的micro RNAs及其靶基因[J].作物学报，2010，36(8)：1324-1335.
[21]Michael Sand,Thilo Gambichler,Daniel Sand,et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science,2009,53:169-175.
[22]Dai Y,Huang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J].Lupus, 2007,16(12):939-46.
[23]Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases[J].BioDrugs,2007,21:97-104.
[24]Tai-You Ha.MicroRNAs in Human Diseases:From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases[J].Immune Network,2011,11(5):227-244.
[251 Shao-yao ying. miRNAs protocols[M].Humana Press Inc,2008,2(1):1-13.
[26]宋莉,王泽剑,等MicroRNAs的研究方法学及其与肿瘤发生发展关系的研究进展[J].中国肿瘤生物治疗杂志,2007.8，14(4)：397-400.
[271 Lu J,Getz G,Miska EA,et al.MicroRNA expression profiles classify human cancers[J].Nature.2005.435(4):834-838.
[281 Neely LA,Patel S,Garver J.elal.A single-molecule method for the quantitation of microRNA gene expression[J].Nat Methods,2006,3(3):41-46.
[291 Brown JR,Sanseau P.A computational view of miRNAs and their targets[J].Drug Discov.Tody,2005,10(1):595-601.
[301 Felicetti F, Errico MC, Bottero L,et al. The promyelocytic leukemia zinc finger-microRNA-22'/-222 pathway controls melanoma progression through multiple oncogenic mechanisms[J].Cancer Res.2008.68(7):2745-54.
[31]Schultz J, Lorenz P, Gross G,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth[J],Cell Res,2008,18(5):549-57.
[321 Worley LA, Long MD, Onken MD,et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling[J]. Melanoma Res,2008,18(1):184-90.
[33]汪阳.miR-199a调控黑色素瘤细胞转移相关基因的筛选[D].中南大学硕士论文,2011.
[341 Kunz M.Schultz J,Ibrahim S.Role of microRNA in melanoma progression[J]. Melanoma Res.2006,16(1):S53-S54.
[351 Hebert C,Norris K, Scheper MA,et al.High mobility group A2 is a target for miRNA-98 in head and neck squamous cell cacrinoma[J]. Mol Cancer.2007.20(6):5-15.
[361 Michael Sand,Thilo Gambichler.Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ [J] Journal of Dermatological Science,2009.53(9):169-175.
[371 Skalsky RL. Samols MA, Plaisance KB. Kaposi.s sarcoma-associated herpesvirus encodes an ortholog of miR-155[J].J Virol,2007,81(4):12836-45.
[381 Zavadil J.Narasimhan M.Blumenberg M.et al.Transforming growth factor-beta and microRNA:Mrna regulatory networks in epithelial plasticity[J].Cells Tissues Organs,2007.185(1-3):157-161.
[39]Dai YHuang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J]. Lupus, 2007,16(12):939-46.
[40]Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis [J].Arthritis Rheum,2010,62(6):1733-1743.
[41]张立民.系统性红斑狼疮MicroRNA表达谱和功能的初步研究[D].中国协和医科大学博士论文,2010：49.
[42]Divekar AA, Dubey S, Gangalum PR,et al.Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells:an apparent paradox in the setting of an inflammatory milieu. J Immunol,2011,186: 924-930.
[43]Bandres E,Cubedo E,Agirre X,et al.Identification by realtime PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J].Mol Cancer,2006,5(1):29-38.
[44]Valastyan S.Reinhardt F,Benaich N.etal.A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis [J].Cell,2009,137(6):1032-1046.
[45]王皓帆.miR-31是一种可抑制乳腺癌转移的多效性microRNA [J]中国病理生理杂志,2010，7：1260.
[46]Wang TS, Liu XB, Wong BY, et al. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue[J].Clin Cancer Res,2008,14(9):2588-2592.
[47]Kozaki K, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer[J]. Cancer Res,2008,68:2094-2105.
[48]Motoyama K,Inoue H.Takatsuno Y.etal.Over-and under-expressed microRNAs in human colorectal cancer[J].Int J Oncol,2009,34(4):1069-1075.
[49]Wang CJ,Zhou ZG,Wang L.etal.Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer[J].Dis Markers,2009,26(1):27-34.
[50]Xi Liu,Lorenzo F,Sempere,et al.MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors[J]. J Clin Invest,2010.120(4):1298-309.
[51]Valastyan S,Benaich N,Chang A,et al.Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis[J].Genes Dev,2009,15;23(22):2592-2597.
[52]Zhang Y,Guo J,Li D.et al.Down-regulation of miR-31 expression in gastric cancer tissues and its elinical significance[J]. Med Oncol.2009,14:685-689.
[53]Guo J,Miao Y,Xiao B,et al.Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues[J].J Gastroenterol Hepatol.2009.24(4):652-7.
[54]Creighton CJ,Fountain MD,Yu Z,et al.Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers[J].Cancer Res.2010,70(5):1906-1915.
[55]Schaefer A,Jung M,Mollenkopf HJ,etal.Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma[J].Int J Cancer,2010,126(5):1166-76.
[56]Hershkovitz Rokah O, Granot G, Ovcharenko A,etal.Downregulation of Mir-31, Mir-155, and Mir-564 in Chronic Myeloid Leukemia Cells. PLoS One.2012;7(4):1-12.
[57]王启鸣.miR-31促进食管鳞癌的侵袭转移[D].郑州大学博士论文,2011：13-14.
[58]Hezova R, Slaby O, Faltejskova Retal.MicroRNA-342,microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients.Cell Immunol 2010,260:70-74.
[59]范薇,唐元家,曲波,等.系统性红斑狼疮患者外周血细胞miR-31的表达[J].上海交通大学学报(医学版),2011,(1)：39-42.
[60]Mattie MD,Benz CC,Bowers J,etal.Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Mol Cancer,2006,5(5):24.
[61]赵东宇,王岩,罗迪.等.生物信息学中的MicroRNA预测研究[J].吉林大学学报(信息科学版),2008,26(3)：276-280.
[62]Zhang Y.miRU:an automated plant miRNA target prediction server.Nucleic Acids Res,2005,33:701-704.
[63]Yu XJ, Li CY, Dai HY, et al. Expression and localization of the activated mitogen-aeti-vated protein kinase in lesional psoriatic skin[J]. xp Mol Patho1, 2007 Dec,83(3):413-418.
[64]MeKenzie RC, Sabin E. Aberrant signalling and transcription factor activation as an explanation for the defective growth control and differentiation of keratihecytes in psoriasis:a hypothesis[J]. Exp Dermatol, Aug 2003,12(4):337-345.
[65]FUnding AT, Johansen C, Kragballe K,et al. Mitogen-and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines[J]. J Invest Dermatol. Aug, 2006,126(8):1784-1791.
[66]Bhoumik A, Fichtman B, Derossi C.et al. Suppressor role of activating transcription factor 2(ATF2) in skin cancer[J]. Proc Natl Acad Sci U S A, 2008,105(5):1674-9.
[67]Wei G, Ku S, Ma GK,et al. HIPK2represses beta-eatenin-mediated-transcription, epidermal stem cell expansion, and skin tumorigenesis[J]. Proc Nail Acad sci U S A,2007,104(32):13040-5.
[68]庞勤,何黎MAPK信号传导通路与相关皮肤病[J].皮肤病与性病.2010,32(4)：15-17.
[69]马景德,齐秀芬MAPKs信号通路及其与疾病关联性的研究现状[J].临床军医杂志.2004,(2)：95-97.
[70]Johnson GL.Lapadat R.Mitogen-activated protein kinase pathways mediated by ERK, JNK. and p38 protein kinases[J]. Science,2002,298:1911-1912.
[71]Cunningham D. Humblet Y. Siena S, et al.Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med,2004,351:337-345.
[72]高泽俊，袁小青,沈捷,MAPK通路在Leptin促人乳腺癌细胞系增殖中的机制研究[J].南京医科大学学报(自然科学版),2008.28(11)：1410-1414.
[73]梁荔,盛红光,刘雯MAPK信号转导通路在DHA诱导胃癌细胞凋亡中的作用[J].中国现代普通外科进展,2009.12(12)：26-29.
[74]刘雯,马金龙,林万润MAPK信号转导蛋白在高温致神经管畸形中的表达[J].中国病理生理杂志,2010,26(3)：472-476.
[75]Msantos SDM, Verveer PJ, Bastiaens PIH. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate[J].Nat Cell Biol,2007,9(3):324-330.
[76]赵海生,顾军MAPK信号转导通路与银屑病[J].中国皮肤性病学杂志,2007,21(3)：184-186.
[77]C.Johansen.k,Kragball,Brinster,R.L,et al.The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin cutaneous[J],Biology,2005.10(11):1365-1369.
[78]Longo K A, W right W S, Kang S, et al. W ntlOb in hibits development of white and brown adipose tissues[J]. J Biol Chem,2004, 279(34):35503-35509.
[79]Ross S E, Hemati N, Longo KA, gt al. MacDougald, Inhibi-tion of adipogenesis by Wnt signaling[J]. Science.2000.289:950-953.
[80]XingY, Clements W K, Kimelman D, et al. Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. Genes Dev,2003,17:2753-2764.
[81]Reischl J, Sehwenke S, Beckman JM, et al. Increased expression of wnt5a in psoriatic plaques [J]. J Invest Dermatol,2007,127(1):163-9.
[82]Saldanha G, Ghura V, PoRer L, et al. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation[J]. Br J Dermato 1, 2004,151(1):157-64.
[83]Taki M, KamataN, Ygkoyama K, et al. Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells[J]. Cancer Sci,2003,94(7):593-7.
[841 Seto ES, Bellen HJ. The ins and outs of Wingless signaling[J]. Trends Cell Biol.2004.14(1):45-53.
[85][13]Eunkyung C, Paul WC, Parkos CA, et al. Amphiregulin causesfunc-tional dowmcgnlation ofadberensjunctions in psoriasis[J]. Invest Dermatol 2005,124(6):1134-4o.
[86]刘国刚，熊霞,Wnt/β-catenin信号通路与银屑病相关性研究进展[J].西南军医,2012,(1)：109-110.
[87]范瑞强，邓丙戌,杨志波.中医皮肤性病学[M].北京：中国中医药出版社出版，2009,566.
[88]陈洪铎.临床诊疗指南-皮肤病与性病分册[M].北京：人民卫生出版社.2006.109-113.
[891 Kerkhof PC. The psoriasis area severity index and altemafive approaches for the assessment of severity:persisting areas of confusion[J].Br J Dermato,1997, 137(4):661-662.
[90]杨水祥miRNA药物治疗前景[C].第六届钱江国际心血管病会议暨2012浙江省心血管病年会.钱江：2012.
[91]李育敏,费嘉,MicroRNA与血液系统肿瘤发生、诊断和治疗[J].中国病理生理杂志,2009,(11)：2225-2229.
[92]Ambros V.The functions of animal microRNAs[J]. Nature,2004,431:350-355.
[93]microRNA在人类癌症治疗中的应用前景[J].分子诊断与治疗杂志,2010,(6).413-416.
[94]王娟,李建民.免疫治疗银屑病对细胞因子影响的研究进展[J].广西医学,2009,(9)：1357-1359.
[95]雷漾,郑和义.T淋巴细胞及细胞因子与银屑病的发病关系[J].国际皮肤性病学杂志,2007,(6)：346-348.
[96]茹雪莹,徐丽敏,吴泰相.白介素-2与银屑病相关性的Meta分析[J].中国中西医结合皮肤性病学杂志,2009,(1)：51-55.
[97]王支琼,李家文.银屑病患者白介素-18及其受体的辅助性非结合链和白介素-18结合蛋白mRNA的表达[J].中华皮肤科杂志,2003,(7)：403.
[981 Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis[J]. Arch Dermatol Res.2001,293:334-342
[99]王学军,陶以成,胡二为.丹槐银屑浓缩丸对豚鼠银屑病模型血清INF-γ、IL-6的影响[J].中国中医药科技,2010,(4)：286.
[100]甄莉,吴媛.黄芪注射液对银屑病外周血淋巴细胞白介素-2及其受体的影响[J].中国中西医结合皮肤性病学杂志,2006,(2)：63-65.
[101]林燕,孙虹,刘艳萍,等.消银合剂治疗血热证银屑病疗效及血清干扰素-γ、白介素-10检测[J].中国中西医结合皮肤性病学杂志,2008,(2)：76-79.
[102]朱黎明,李英,孙兆圣,等.消银脐贴治疗寻常型银屑病24例临床研究[J].江苏中医药,2011,(5)：40-41.
[103]王丽华,张蕾,刘欣,等.养血解毒汤对血燥型银屑病患者血清免疫细胞因子的调节[J].辽宁中医药大学学报,2010,(11)：69-71.
[104]吴胜利,许能,陈建明,等.解毒化疲汤治疗银屑病的临床和实验研究[J].中华皮肤科杂志,2004,37(3)：133-34.
[105]宋茹,袁继民,王媛媛.复方苦参注射液治疗银屑病的实验研究[J].中国现代应用药学杂志,2002,19(3)：177-178.
[106]景海霞,盛晚香,段德鉴.当归多糖对豚鼠银屑病样皮损中PCNA表达的影响.中国皮肤性病学杂志,2008,22(1)：11-13.
[107]杨志波,向亚萍,欧阳恒银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子αα水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[1]Ambros V.The functions of animal microRNAs[J]. Nature,2004,431:350-355.
[2]Griffiths-Jones S,Saini HK,van Dongen S,et al.miRBase:tools for microRNA genomics[J].Nucleic Acids Res,2008.36:154-158.
[3]Shao-yao ying. miRNA protocols[M].Humana Press Inc,2008,2:1-13.
[4]Eniko Sonkoly.Tianling Weil,Peter C.J,et al.MicroRNAs:Novel Regulators Involved in the Pathogenesis of Psoriasis[J].PLoS ONE,2007,7(7):1-8.
[5]E.Sonkoly.M.Stahle.A.Pivarcsi.MicroRNAs:novel regulators in skin inflammation[J]. Clinical and Experimental Dermatology,2008,33:312-315.
[6]Eniko Sonkoly,Mona Stahle,Andor Pivarcsi. MicroRNAs and immunity:Novel players in the regulation of normal immune function and inflammation[J].Seminars in Cancer Biology,2008,18:131-140.
[7]Lee,R.C,Feinbanum,R.L,Ambros,V.The C.elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity ti lin-14[J].Cell,1993,75:843-854.
[8]Lau,N.C,Lim.L.P,Weinstein.E.G, Bartel,D.P.An abundant class of tiny RNAs with probable regulatory roles in Caenorhabiditis elegans.Science[J].2001,294:858-862.
[9]Lagos-Quintana.M.Rauhut.R.Meyer et al.New miRNA from mouse and human[J].RNA.2003,9:175-179. Calin GA,Sevignani C.Dumitru CD,et al.Hunman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J].Proc Natl Acad Sci USA,2004,101:2999-3004.
[11]薛京伦,等.表观遗产学—原理、技术与实践[M].第一版,上海：上海科技出版社.2006.12：131-146.
[12]Khvorova.A,Reynolds.A.Jayasena.S.D.Functional siRNAs and miRNA exhibit strand bias[J].Cell,2003.115:209-216.
[13]Soken T.Yasushi O,Gozoh T.MicroRNA:biogenetic and functional mechanisms and involvementsin cell differentiation and cancer[J].J Pharmacol Sci,2006,101:267-270.
[14]Lu J,Getz G,Miska EA.et al.MicroRNA expression profiles classify human cancers[J].Nature,2005,435:834-838.
[15]Neely LA,Patel S.Garver J,elal.A single-molecule method for the quantitation of microRNA gene expression[J].Nat Methods,2006,3:41-46.
[16]Mattie MD,Benz CC,Bowers J,etal.Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies[J].Mol Cancer.2006,5:24.
[17]Brown JR,Sanseau P.A computational view of miRNA and their targets[J].Drug Discov.Tody,2005,10:595-601.
[18]Landthaler M.Yalcin A,Tuschl T.The human DiGeorge syndrome critical region gene 8 and Tts D.melanogaster homolog are required for miRNA biogenesis[J].Curr boil,2004.14:2162-2167.
[19]宋莉,王泽剑,等.MicroRNAs的研究方法学及其与肿瘤发生发展关系的研究进展[J].中国肿瘤生物治疗杂志,2007.8,14(4)：397-400.
[20]Michael Sand,Thilo Gambichler, Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science.2009.53:169-175.
[21]Zhang L,Huang J,Yang N.et al.microRNAs exhibit high frequency genomic alterations in human cancer[J].Proc Natl Acad Sci USA.2006.103:9136-41.
[22]Feramisco JD, Casey R. Tsao H. Recent updates on genetics:teaching old dogmas new tricks[J].Pediatr dermatol,2008.25(1):99-108.
[23]Gaur A.Jewell DA. Liang Y,et al. Characterizationof and their biological correlates in human cancer cell lines[J].Cancer Res.2007,67:2456-68.
[24]Bemis LT. Chen R, Amato CM.et al.Robinson WA:MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines[J]. Cancer Res,2008,68:1362-8.
[25]Felicetti F, Errico MC, Bottero L,et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms[J].Cancer Res,2008,68:2745-54.
[26]Schultz J, Lorenz P, Gross G,et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth[J],Cell Res,2008,18:549-57.
[27]Worley LA, Long MD, Onken MD,et al. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling[J].Melanoma Res,2008,18:184-90.
[28]Kunz M,Schultz J,Jbrahim S.Role of microRNA in melanoma progression[J].Melanoma Res,2006,16(suppl):S53-S54.
[29]Hebert C,Norris K, Scheper MA.et al.High mobility group A2 is a target for miRNA-98 in head and neck squamous cell cacrinoma[J]. Mol Cancer.2007,20 (6):5-15.
[30]Michael Sand.Thilo Gambichler.Daniel Sand.et al. MicroRNAs and the skin:Tiny players in the body's largest organ[J].Journal of Dermatological Science, 2009,53:169-175.
[31]Skalsky RL, Samols MA, Plaisance KB. Kaposis sarcoma-associated herpesvirus encodes an ortholog of miR-155[J].J Virol,2007.81:12836-45.
[32]Zavadil J.Narasimhan M.Blumenberg M.et al.Transforming growth factor-beta and microRNA:Mrna regulatory networks in epithelial plasticity[J].Cells Tissues Organs,2007,185(1-3):157-161. ] Dai Y,Huang YS,Tang M,et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients[J].Lupus. 2007,16(12):939-46.
[34]Lebwohl M.Psoriasis[M]. The Lancet.2003.361:1197-1204.
[35]Vickery BP.Skin barrier function in atopic dermatitis[J].Curr Opin Pediatr, 2007.19:89-93.
[1]Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis.Nature 2007;445:866-873
[2]刘旭,刁骋.银屑病发病机制的研究进展[J].沈阳医学院学报,2007.12,9(4)：248-250.
[3]张学军.全基因组关联分析对银屑病遗传学研究的启示[J].浙江大学学报(医学版)2009,38(4)：334-336.
[4]Gallinaro H.A 4.2 kb upstream region of the human comeodesmosin gene directs site-specific expression in hair follicles and hyperkeratotic epidermis of transgenie mice[J].J Invest Derm atol,2004.122:730-738.
[5]Foerster J,Nohe I,Schweiger S,et al. Evaluation of the IRF-2 gene as a candidate for PSORS3[J].J Invest Dermatol.2004,122(1):61-64.
[6]Hufmeier U,Lascorz J,Traupe H,et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confinns a role in susceptibility to psoriasis vulgaris[J]. J Invest Dermatol,2005.125 (5):906-912.
[7]Rainer Z,Robert,E,Lukas K,et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Junproteins[J]. Nature.2005,437: 369-375.
[8]ZHANG X J, HUANG W, YANG S, et al.,Psoriasis genome-wide association study identifies susceptibility variants with in LCE gene cluster at 1q21 [J]. Nat Genet,2009,41 (2):205-210.
[9]徐娟,贾随旺,钟绮丽,等.银屑病皮损细胞凋亡的研究[J].岭南皮肤性病科杂志,2004,11(2)：91-93
[10]陈静,鲁建云,廖朝晖,等.角质形成细胞凋亡与银屑病病情的关系[J].中南大学学报(医学版),2006,31(6)：936-939
[11]Oieda R,Sanchez Regana M,Massana J,et al. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study [J]. J Dermatolog Treat,2005,16(4):238-241.
[12]Banno T,Gazel A,Blumenberg M. Efects of tumor necrosis factor-a(TNF-a) in epidermal keratinocytes revealed using global transcriptional profiling[J]. J Biol Chem,2004,279:32633-32642.
[13]Sabat R,Wallace E,Endesfelder S.et al. IL-19 and IL-20:two novel cytokines with importance in inflammatory diseases[J]. Expert Opin TherTargets,2007,11(5):601-612.
[14]Gamze P,Regien MR,Jan DB. In vitro and in situ expression of IL-23 buy keratinocytes in healthy skin and psoriasis lesions:enhanced expression in psoriatic skin[J]. J Immunol,2006.176 (3):1908-1915.
[15]路又璐.17味中药对培养的表皮细胞增殖的影响[J].临床皮肤科杂志,1996,25(4)：202.
[16]刘晓明,孙秀坤,齐欣等.20种中药灌胃对小鼠上皮细胞增殖和表皮细胞分化及血浆内皮素-1的影响[J].中华皮肤科杂志,2001,34(4)：282-283.
[17]吴胜利,许能,陈建明,等.解毒化疲汤治疗银屑病的临床和实验研究[J].中华皮肤科杂志,2004,37(3)：133-34
[18]宋茹,袁继民,王媛媛.复方苦参注射液治疗银屑病的实验研究[J].中国现代应用药学杂志,2002,19(3)：177-178
[19]景海霞,盛晚香,段德鉴.当归多糖对豚鼠银屑病样皮损中PCNA表达的影响.中国皮肤性病学杂志,2008,22(1)：11-13
[20]杨志波,向亚萍,欧阳恒银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子α水平的比较[J].中华皮肤科杂志,2000,33(6)：423-424.
[21]王万春,熊佳玫,马文军,等.中药清银解毒汤治疗寻常型银屑病及血清TNF-α、IL-8水平检测[J].辽宁中医杂志,2009,36(2)：242-243
[22]于延,刘晓明,侯素春.凉血活血汤治疗寻常型银屑病临床观察及其对血IL-8的影响[J].中国麻风皮肤病杂志,2005,21(9)：712-714
[23]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771
[24]陈红,王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J].中药材,2004,27(11)：885-886
[25]马学伟,陈国荣,朱风梅,等克银Ⅰ号胶囊治疗进行期寻常型银屑病40例临 床观察[J].中国中医药科技,2000,7(6)：396
[26]王乖娟,刘卫兵,荆鲁华,等.银屑宁胶囊对心得安致豚鼠银屑病样皮损N0和MDA水平的影响[J].中国中西医结合皮肤性病学杂志,2005,4(3)：166.
[27]刘群英,钟以泽,陈德华,等.白疙软膏治疗银屑病的实验研究[J].广西医科大学学报,2006,23(3)：421-422.
[28]王禾,王萍,孙丽蕴,等.凉血活血胶囊治疗银屑病血热证的临床观察及外周血淋巴细胞亚群检测[J].中国皮肤性病学杂志,2004,18(3)：176-177
[29]王丽江,张地君,粟小文.寻常型银屑病患者丹参治疗前后甲皱微循环变化比较析[J].皮肤病与性病,2001,23(4)：3
[30]娄卫海,张志礼,邓丙戌,等.凉血活血汤治疗进行期银屑病的临床及实验研究[J].华皮肤科杂志,1999,32(2)：80-81.
[31]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿留坏死因子和介素8水平检测[J].临床皮肤科杂志,2002,31(12)：770-771.